Brind.
  1. A company with a subsidiary in the Netherlands sold it to AVS Bio, using the proceeds to invest in an AI-based SaaS platform.

The divestiture timeline for the Dutch subsidiary of ImmunoPrecise Antibodies Ltd. has been extended beyond initial expectations.

1 report, 1 independent Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The divestiture timeline for the Dutch subsidiary of ImmunoPrecise Antibodies Ltd. has been extended beyond initial expectations.

Keep exploring

Part of

A company with a subsidiary in the Netherlands sold it to AVS Bio, using the proceeds to invest in an AI-based SaaS platform. All 2 developments

Coverage

Newest first; wire copies grouped
  • GuruFocus.comImmunoPrecise Antibodies Ltd (IPA) Q4 2025 Earnings Call Highlights: Record Revenue and ... Revenue: $7 million in Q4, highest quarterly revenue in company's history; $24.5 million for fiscal year 20